| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-13 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-13 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-12 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.24 | 8e-12 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-11 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-11 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-11 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.24 | 5e-11 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-11 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |